The stock of Cognition Therapeutics Inc (CGTX) has seen a -16.17% decrease in the past week, with a -6.68% drop in the past month, and a -40.64% decrease in the past quarter. The volatility ratio for the week is 9.25%, and the volatility levels for the past 30 days are at 11.79% for CGTX. The simple moving average for the last 20 days is -11.72% for CGTX stock, with a simple moving average of -67.88% for the last 200 days.
Is It Worth Investing in Cognition Therapeutics Inc (NASDAQ: CGTX) Right Now?
Additionally, the 36-month beta value for CGTX is 1.32. There are mixed opinions on the stock, with 3 analysts rating it as a “buy,” 1 rating it as “overweight,” 1 rating it as “hold,” and 0 rating it as “sell.”
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The public float for CGTX is 33.80M and currently, short sellers hold a 2.41% ratio of that float. The average trading volume of CGTX on November 20, 2024 was 520.63K shares.
CGTX) stock’s latest price update
The stock price of Cognition Therapeutics Inc (NASDAQ: CGTX) has surged by 1.41 when compared to previous closing price of 0.44, but the company has seen a -16.17% decline in its stock price over the last five trading sessions. globenewswire.com reported 2024-11-13 that – CT1812 slowed cognitive decline by 95% in Alzheimer’s disease patients with lower levels of plasma p-tau217 in a pre-specified analysis from Phase 2 SHINE study presented at CTAD –
Analysts’ Opinion of CGTX
Oppenheimer, on the other hand, stated in their research note that they expect to see CGTX reach a price target of $22. The rating they have provided for CGTX stocks is “Outperform” according to the report published on November 03rd, 2021.
B. Riley Securities gave a rating of “Buy” to CGTX, setting the target price at $27 in the report published on November 03rd of the previous year.
CGTX Trading at -8.74% from the 50-Day Moving Average
After a stumble in the market that brought CGTX to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -84.74% of loss for the given period.
Volatility was left at 11.79%, however, over the last 30 days, the volatility rate increased by 9.25%, as shares sank -24.63% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -25.59% lower at present.
During the last 5 trading sessions, CGTX fell by -15.81%, which changed the moving average for the period of 200-days by -79.90% in comparison to the 20-day moving average, which settled at $0.5101. In addition, Cognition Therapeutics Inc saw -75.66% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at CGTX starting from Ricciardi Lisa, who purchase 5,700 shares at the price of $1.75 back on Mar 14 ’24. After this action, Ricciardi Lisa now owns 291,345 shares of Cognition Therapeutics Inc, valued at $9,975 using the latest closing price.
Stock Fundamentals for CGTX
Current profitability levels for the company are sitting at:
- -157.08 for the present operating margin
- 0.49 for the gross margin
The net margin for Cognition Therapeutics Inc stands at -92.12. The total capital return value is set at -3.93. Equity return is now at value -157.90, with -103.30 for asset returns.
Based on Cognition Therapeutics Inc (CGTX), the company’s capital structure generated 0.04 points at debt to capital in total, while cash flow to debt ratio is standing at -44.05. The debt to equity ratio resting at 0.04. The interest coverage ratio of the stock is -2540.52.
Currently, EBITDA for the company is -25.51 million with net debt to EBITDA at 0.56. When we switch over and look at the enterprise to sales, we see a ratio of -7.25. The liquidity ratio also appears to be rather interesting for investors as it stands at 2.11.
Conclusion
In conclusion, Cognition Therapeutics Inc (CGTX) has seen bad performance in recent times. Analysts have a bullish opinion on the stock, with some rating it as a “buy” and others rating it as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
